Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569800 | 0.83 | SIGMAR1 (0.49) | SIGMAR1MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL408760 | 0.83 | KMT2A (0.44) | SIGMAR1MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL14558149 | 0.82 | MEN1 (0.48) | SIGMAR1MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL463093 | 0.82 | ALDH1A1 (0.44) | SIGMAR1MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL13306955 | 0.82 | SIGMAR1 (0.73) | SIGMAR1MAOBCARM1PRMT6PRMT8 | |
| SCHEMBL14569583 | 0.81 | ACHE (0.57) | OPRM1ACHEBCHE | |
| SCHEMBL792219 | 0.80 | SIGMAR1 (0.71) | SIGMAR1MAOB | |
| SCHEMBL7934310 | 0.80 | ALDH1A1 (0.43) | SIGMAR1MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL12680198 | 0.79 | ALDH1A1 (0.71) | MEN1ALDH1A1POLBKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8694185 | 0.79 | SIGMAR1 (0.69) | SIGMAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | SIGMAR1 3649/4885MEN1 3283/4885ALDH1A1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.